INNOVENT BIO (01801) reported third-quarter product revenue exceeding RMB4.7 billion, up more than 40% year on year.

INNOVENT BIO (01801) announced that in the third quarter of 2026, the Company's business sustained strong growth momentum, with product revenue exceeding RMB4.7 billion, up more than 40% year on year, fully confirming the strong momentum and continued delivery of its dual-engine strategy. Market penetration continued to increase for key new products in the comprehensive pipeline, including Xermeo (mazdutide injection), Xinbile (tarcocimab injection), and Xinbimin (teprotumumab N01 injection); within the oncology product line, multiple tyrosine kinase inhibitor (TKI) products achieved rapid sales growth, jointly driving overall growth of the Company's commercialized product portfolio. The diversified product matrix is delivering synergistic strength, driving continuous optimization of the revenue structure and further enriching its growth engines. In 2026, the Company maintained high-quality rapid growth, further consolidating its industry position as a leading innovative biopharmaceutical company in China, while continuing to demonstrate investment value characterized by both certainty and high growth potential. In global innovation, the Company is advancing three core assets into global Phase III clinical development and continues to expand its next-generation innovative pipeline in oncology, cardiovascular and metabolic (CVM) diseases, autoimmune diseases, and ophthalmology. Currently, a total of 41 pipeline assets are in clinical-stage development, and more than 100 early-stage R&D projects are progressing in an orderly manner. Its global innovative pipeline reserve is building strong momentum, with ample growth drivers. At the same time, the Company has more than 20 collaborative R&D projects with multinational pharmaceutical companies such as Pfizer, Eli Lilly, Takeda, and Roche, including five co-development and co-commercialization (Co-Co) pipelines, with its global innovation capabilities continuing to gain further international recognition. The Company is currently in a critical window period of strategic leapfrogging, fully advancing its transformation from a leading domestic biopharmaceutical company to a world-class biopharmaceutical company. Looking toward 2030, the Company has anchored its core strategic goals: to achieve total revenue of RMB35 billion to RMB40 billion, reach profitability levels comparable to leading pharmaceutical companies, advance at least five candidate molecules into global multicenter Phase III development, and achieve product launches in major European and U.S. markets. The Company will continue to deepen original innovation, accelerate its international layout, and adhere to high-quality growth, creating long-term sustainable value for patients, shareholders, and society.